Hologic, Inc. (HOLX)Healthcare | Medical Instruments & Supplies | Marlborough, United States |
USD
Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ★☆☆☆☆ |
Hot Take | April 19, 2026, 4:05 a.m. UTC
Hologic is trading at an all-time high following a confirmed private equity buyout by Blackstone and TPG ($17.3B deal), creating a binary short-term scenario where further upside is capped until a new company structure emerges; fundamentally, the company is facing earnings contraction (-9.2% growth) and high valuation (1.66x PEG), while the complete absence of dividends over the last 5 years invalidates any income thesis. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.002431 |
| AutoARIMA | 0.003586 |
| AutoETS | 0.003586 |
| MSTL | 0.003657 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.81 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.578 |
| Excess Kurtosis | 0.08 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 48.051 |
| Revenue per Share | 18.366 |
| Market Cap | 16,968,846,336 |
| Trailing P/E | 31.54 |
| Forward P/E | 15.66 |
| Beta | 0.70 |
| Profit Margins | 13.18% |
| Website | https://www.hologic.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.34530973 |
| Address1 | 250 Campus Drive |
| All Time High | 87.88 |
| All Time Low | 0.4219 |
| Ask | 79.83 |
| Ask Size | 100 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 13,350,057 |
| Average Volume | 4,506,784 |
| Average Volume10Days | 13,350,057 |
| Beta | 0.703 |
| Bid | 75.99 |
| Bid Size | 5,000 |
| Board Risk | 5 |
| Book Value | 23.514 |
| City | Marlborough |
| Compensation Risk | 6 |
| Country | United States |
| Currency | USD |
| Current Price | 76.01 |
| Current Ratio | 4.04 |
| Date Short Interest | 1,773,360,000 |
| Day High | 76.04 |
| Day Low | 76.0 |
| Debt To Equity | 48.051 |
| Earnings Growth | -0.092 |
| Earnings Quarterly Growth | -0.109 |
| Ebitda | 1,350,700,032 |
| Ebitda Margins | 0.32731998 |
| Enterprise To Ebitda | 12.677 |
| Enterprise To Revenue | 4.149 |
| Enterprise Value | 17,122,545,664 |
| Exchange | NMS |
| Exchange Timezone Name | UTC |
| Fifty Day Average | 75.3112 |
| Fifty Two Week High | 76.07 |
| Fifty Two Week Low | 51.9 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 636,301,800 |
| Float Shares | 221,206,679 |
| Forward Eps | 4.861 |
| Forward P E | 15.664253 |
| Free Cashflow | 848,612,480 |
| Full Time Employees | 7,070 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.60378 |
| Gross Profits | 2,491,500,032 |
| Held Percent Insiders | 0.00836 |
| Held Percent Institutions | 0.96516 |
| Implied Shares Outstanding | 223,244,905 |
| Industry | Medical Instruments & Supplies |
| Industry Disp | Medical Instruments & Supplies |
| Industry Key | medical-instruments-supplies |
| Ir Website | http://investors.hologic.com/ |
| Last Fiscal Year End | 1,758,931,200 |
| Last Split Date | 1,207,180,800 |
| Last Split Factor | 2:1 |
| Long Business Summary | Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. It also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analysis software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology systems; and breast conserving surgery products. In addition, the company provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system. The company sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts. |
| Long Name | Hologic, Inc. |
| Market Cap | 16,968,846,336 |
| Max Age | 86,400 |
| Message Board Id | finmb_108544 |
| Most Recent Quarter | 1,766,793,600 |
| Net Income To Common | 543,800,000 |
| Next Fiscal Year End | 1,790,467,200 |
| Non Diluted Market Cap | 16,968,845,229 |
| Number Of Analyst Opinions | 9 |
| Open | 76.01 |
| Operating Cashflow | 1,097,699,968 |
| Operating Margins | 0.22990999 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 508 263 2900 |
| Previous Close | 76.01 |
| Price Hint | 2 |
| Price To Book | 3.2325425 |
| Price To Sales Trailing12 Months | 4.1121645 |
| Profit Margins | 0.13178 |
| Quick Ratio | 3.102 |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 3.0 |
| Regular Market Day High | 76.04 |
| Regular Market Day Low | 76.0 |
| Regular Market Open | 76.01 |
| Regular Market Previous Close | 76.01 |
| Regular Market Volume | 101,956,189 |
| Return On Assets | 0.07434 |
| Return On Equity | 0.108559996 |
| Revenue Growth | 0.025 |
| Revenue Per Share | 18.366 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 223,244,905 |
| Shares Percent Shares Out | 0.0318 |
| Shares Short | 7,100,246 |
| Shares Short Previous Month Date | 1,770,940,800 |
| Shares Short Prior Month | 4,834,145 |
| Short Name | Hologic, Inc. |
| Short Percent Of Float | 0.0366 |
| Short Ratio | 2.78 |
| State | MA |
| Symbol | HOLX |
| Target High Price | 78.0 |
| Target Low Price | 76.0 |
| Target Mean Price | 76.66667 |
| Target Median Price | 76.0 |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 2,366,599,936 |
| Total Cash Per Share | 10.601 |
| Total Debt | 2,520,300,032 |
| Total Revenue | 4,126,500,096 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.41 |
| Trailing P E | 31.53942 |
| Trailing Peg Ratio | 1.6608 |
| Two Hundred Day Average | 71.65167 |
| Underlying Symbol | HOLX |
| Uuid | 1ee39b1d-2fdb-3e89-8451-1d8ac5dfb834 |
| Volume | 101,956,189 |
| Website | https://www.hologic.com |
| Zip | 1,752 |